[go: up one dir, main page]

Jope, 1999 - Google Patents

Cholinergic muscarinic receptor signaling by the phosphoinositide signal transduction system in Alzheimer's disease

Jope, 1999

Document ID
16453596383032801737
Author
Jope R
Publication year
Publication venue
Journal of Alzheimer’s Disease

External Links

Snippet

Recent years have seen the advent of new methods capable of measuring the activity of receptor-coupled, G-protein-mediated, phosphoino-sitide second messenger production in membranes prepared from postmortem human brain. Considering the interest in treating …
Continue reading at journals.sagepub.com (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701G01N2333/4701
    • G01N2333/4709Amyloid plaque core protein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds

Similar Documents

Publication Publication Date Title
Pîrşcoveanu et al. Tau protein in neurodegenerative diseases-a review
US9188595B2 (en) Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation
Lee Disruption of the cytoskeleton in Alzheimer's disease
Pacheco et al. Phosphoinositide signaling in human brain
Sergeant et al. Tau protein as a differential biomarker of tauopathies
Halliday et al. Neuropathology underlying clinical variability in patients with synucleinopathies
Pointer et al. Cardiolipin in central nervous system physiology and pathology
Giacomini et al. A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies
Jing et al. Altered subcellular distribution of c-Abl in Alzheimer's disease
Gong et al. Dysregulation of protein phosphorylation/dephosphorylation in Alzheimer′ s disease: a therapeutic target
Cárdenas-Aguayo et al. Physiological role of amyloid beta in neural cells: the cellular trophic activity
US20130123133A1 (en) Screening methods
Grimm et al. Altered membrane fluidity and lipid raft composition in presenilin‐deficient cells
US20240192235A1 (en) Ceramide and spingomyelin in neurological disorders
Hernández et al. GSK-3 dependent phosphoepitopes recognized by PHF-1 and AT-8 antibodies are present in different tau isoforms
Pandey et al. Altered expression and phosphorylation of myristoylated alanine-rich C kinase substrate (MARCKS) in postmortem brain of suicide victims with or without depression
Jope Cholinergic muscarinic receptor signaling by the phosphoinositide signal transduction system in Alzheimer's disease
Nitsch et al. Regulation of proteolytic processing of the amyloid β-protein precursor of Alzheimer’s disease in transfected cell lines and in brain slices
Uno et al. Efficacy of a novel, orally active GSK-3 inhibitor 6-Methyl-N-[3-[[3-(1-methylethoxy) propyl] carbamoyl]-1H-pyrazol-4-yl] pyridine-3-carboxamide in tau transgenic mice
Zhang et al. Hydrogen sulfide-induced processing of the amyloid precursor protein in SH-SY5Y human neuroblastoma cells involves the PI3-K/Akt signaling pathway
Gibb et al. Differential involvement and heterogeneous phosphorylation of tau isoforms in progressive supranuclear palsy
WO2022221559A2 (en) Ceramide and sphingomyelin in neurological disorders
Carpinteiro Study of the neuronal molecular mechanisms in TAU uptake
Tjiang Mitochondrial Distribution and Dynamics at the Axon Initial Segment and their Influence on TAU-Trafficking
Chandrol et al. Recent Progress in Alzheimer’s Disease: Pathophysiology, Newer Natural & Synthetic Inhibitors, and Therapeutic Targets